v3.26.1

Intangible Assets, Net | 6 Months Ended | 12 Months Ended
--- | --- | ---
Nov. 30, 2025 | Dec. 31, 2025 | May 31, 2025
Intangible Assets, Net [Line Items] |  |  |
INTANGIBLE ASSETS, NET |  | 8. INTANGIBLE ASSETS, NET
|  | December 31, 2025 |  | December 31, 2024
Gross carrying amount |  |  |  |  |  |
Prepaid patented licenses |  | $ | 200,000 |  | $ | 200,000
Computer software |  |  | 223,858 |  |  | 223,858
|  |  | 423,858 |  |  | 423,858
Less: accumulated amortization |  |  |  |  |  |
Prepaid patented licenses |  |  | 200,000 |  |  | 200,000
Computer software |  |  | 223,858 |  |  | 223,858
|  |  | 423,858 |  |  | 423,858
Intangible assets, net |  |  |  |  |  |
Prepaid patented licenses |  |  | — |  |  | —
Computer software |  |  | — |  |  | —
Intangible assets, net |  | $ | — |  | $ | —
Prepaid patented licenses and computer software are finite-lived intangible assets which are amortized over their estimated useful life. Amortization expenses for finite-lived intangible assets amounted to $nil and $19,219 for the year ended December 31, 2025 and 2024 respectively. For the year ended December 31, 2023, the Group terminated two of the licenses. For the year ended December 31, 2024, the Group terminated four of the licenses. For the year ended December 31, 2025, the Group terminated 5 of the licenses. The Group considered that the carrying amount of these intangible assets are not recoverable and are fully impaired. As a result, the Group recorded $519,496 impairment loss on intangible assets in research and development expenses for the year ended December 31, 2023. Besides, an impairment loss related to the computer software for Hong Kong healthcare services amounted to $128,128 was recorded in research and development expenses, and $1,841 was recorded in other operating expenses for the year ended December 31, 2024 and 2023, respectively. There is no such impairment loss during the year ended December 31, 2025. The Group does not expect any amortization expense related to its finite-lived intangible assets for the next five years and thereafter to be as follows as of December 31, 2025. |
DiamiR Biosciences Corp. [Member] |  |  |
Intangible Assets, Net [Line Items] |  |  |
INTANGIBLE ASSETS, NET | NOTE 6 — INTANGIBLE ASSETS In the Company’s fiscal year ended May 31, 2021, the Company acquired laboratory assets and operations, including the laboratory’s CLIA certification and its state operating licenses from a provider of molecular diagnostic tests. The Company allocated $197,761 of the total purchase price to the certification and licenses, which it considers indefinite-lived intangible assets. |  | NOTE 5 — INTANGIBLE ASSETS In the Company’s fiscal year ended May 31, 2021, the Company acquired laboratory assets and operations, including the laboratory’s CLIA certification and its state operating licenses from a provider of molecular diagnostic tests. The Company allocated $197,761 of the total purchase price to the certification and licenses, which it considers indefinite-lived intangible assets.

X
- References No definition available. + Details
Name: | apm_IntangibleAssetsNetLineItems
Namespace Prefix: | apm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=apm_DiamiRBiosciencesCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |